Trilantic Europe has acquired a 90% stake in Doppel Farmaceutici, a leading CDMO in Italy, to leverage the expected growth in the pharmaceutical outsourcing sector.

Information on the Target

Doppel Farmaceutici ('Doppel' or the 'Company') is a prominent player in Italy's pharmaceutical landscape, specializing in research, development, formulation, manufacturing, and packaging. The company operates exclusively as a Contract Development and Manufacturing Organization (CDMO) for third parties, providing valuable services to various clients. With its establishment dating back to 1994, Doppel has developed strong partnerships with blue-chip companies and holds a significant market position.

Currently, Doppel employs 460 professionals and operates from two production facilities located in Cortemaggiore and Rozzano, Italy. The Company is primarily engaged in the manufacturing and packaging of a diverse range of pharmaceutical products, including pills, tablets, creams, and injection vials, all produced under stringent aseptic conditions or utilizing terminal sterilization methods. In addition to pharmaceuticals, Doppel has expanded its offerings to include food, nutraceutical, and cosmetic supplements as well as medical devices.

Industry Overview in Italy

The pharmaceutical sector in Italy is noteworthy for its robust growth and innovation. Italy ranks as one of the largest pharmaceutical markets in Europe, driven by continuou